{
    "clinical_study": {
        "@rank": "115942", 
        "arm_group": {
            "arm_group_label": "Enfuvirtide monotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for \u2265 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens."
        }, 
        "brief_summary": {
            "textblock": "To find out if it is possible for HIV-1 patients to maintain antiretroviral medications\n      during allogeneic bone marrow transplant"
        }, 
        "brief_title": "Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "detailed_description": {
            "textblock": "Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during\n      allogeneic hematopoietic stem cell transplant (HSCT).  The primary outcome is the fraction\n      of patients who maintain any form of anti-retroviral therapy, including enfuvirtide\n      monotherapy, through day 60 post-transplant.  If patients are unable to take oral\n      anti-retroviral medications, but are able to tolerate subcutaneous enfuvirtide monotherapy\n      this will be considered maintenance of ART.  Failure to maintain ART will be defined as \u2265 24\n      hours without any anti-retroviral therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 infection, as documented by a rapid HIV-1 test or any FDA-approved HIV-1 enzyme\n             or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at\n             any time prior to study entry.  Alternatively, two HIV-1 RNA values > 200 copies/mL\n             at least 24 hours apart performed by any laboratory that has CLIA certification, or\n             its equivalent may be used to document infection.\n\n          -  Patients must be \u2265 18 years of age.\n\n          -  Plan to undergo a Myeloablative, HLA matched or partially HLA-mismatched\n             (haploidentical), related-donor bone marrow transplantation that includes high-dose\n             posttransplantation Cy using bone marrow from a related donor:\n\n          -  Plan to undergo a Nonmyeloablative, HLA matched or partially HLA-mismatched,\n             related-donor bone marrow transplantation that includes high-dose posttransplantation\n             Cy using bone marrow from a related donor:\n\n        Exclusion Criteria:\n\n        - Patients with a known history of enfuvirtide resistance will not be eligible for this\n        trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836068", 
            "org_study_id": "J1331", 
            "secondary_id": "NA_00083734"
        }, 
        "intervention": {
            "arm_group_label": "Enfuvirtide monotherapy", 
            "description": "Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for \u2265 24 hours, or during periods when ART is held due to interactions", 
            "intervention_name": "Enfuvirtide", 
            "intervention_type": "Drug", 
            "other_name": "Fuzeon"
        }, 
        "intervention_browse": {
            "mesh_term": "Enfuvirtide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV positive", 
            "HIV-1", 
            "Bone Marrow Transplant", 
            "Allogeneic BMT", 
            "BMT"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "rambind1@jhmi.edu", 
                "last_name": "Richard Ambinder, Md. PhD", 
                "phone": "410-955-8839"
            }, 
            "contact_backup": {
                "email": "christinedurand@jhmi.edu", 
                "last_name": "Christine Durand, MD", 
                "phone": "410-502-1003"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "The Sidney Kimmel Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Richard Ambinder, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals", 
        "other_outcome": {
            "description": "Describe the incidence and severity of acute and chronic graft-vs-host disease", 
            "measure": "The incidence and severity of acute and chronic graft-vs-host disease", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "rambind1@jhmi.edu", 
            "last_name": "Richard Ambinder, M.D., PhD", 
            "phone": "410-955-8839"
        }, 
        "overall_contact_backup": {
            "email": "christinedurand@jhmi.edu", 
            "last_name": "Christine Durand, M.D.", 
            "phone": "410-502-1003"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Richard Ambinder, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Failure to maintain anti retroviral therapy for 24 hours", 
            "measure": "Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during allogeneic HSCT", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836068"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measure the number of copies of HIV-1 DNA per million peripheral blood mononuclear cells at baseline 12, 24, 36, and 52 weeks", 
            "measure": "Measure copies of HIV-1 DNA in blood mononuclear cells", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}